Dactinomycin

Evidence Level: L5

Predicted Indications: 4

Dactinomycin

Pharmacist Assessment Report

Dactinomycin: cytotoxic DNA-intercalating antineoplastic → relapsing-remitting multiple sclerosis

One-Sentence Summary

Dactinomycin is a cytotoxic antineoplastic that intercalates into DNA and inhibits transcription. The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis, with a score of 0.9958. No clinical trials and no publications directly study this disease, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Relapsing-remitting multiple sclerosis
TxGNN Prediction Score	0.9958
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Dactinomycin is generally known as a transcription-inhibiting DNA intercalator with cytotoxic and myelosuppressive effects.

A rationale for immunomodulation in a relapsing autoimmune demyelinating disease is speculative at best. Many approved disease-modifying therapies already exist for this condition, and dactinomycin’s toxicity profile makes it a poor fit by comparison. The high score is therefore likely a model artifact rather than a validated signal, and it should not be read as evidence of efficacy.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
00213071	COSMEGEN	Not recorded	Not recorded

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (DNA-intercalating antibiotic class)
Myelosuppression Risk	High. Bone marrow suppression is expected, and the drug interaction and contraindication data point to blood-count risks
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential, liver and renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Conditions flagged as contraindication-related: liver disease, gallbladder disease, thrombocytopenia, neutropenia, agranulocytosis, anemia, leukopenia, aplastic anemia, varicella zoster infection and herpes zoster, hepatic vein thrombosis and Budd-Chiari syndrome. These are relation-level signals and are not label text.
Drug Interactions: 100 interactions were found. Major-level ones include deferiprone and samarium (153Sm) lexidronam. Moderate-level ones include palifermin, strontium chloride Sr-89, fostamatinib, mercaptopurine, roflumilast and chloramphenicol.

Please also refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The score is very high, but no trial or publication studies dactinomycin in relapsing-remitting multiple sclerosis. Its cytotoxic, myelosuppressive profile is a poor match for a chronic autoimmune disease with many approved alternatives.

To proceed, the following is needed:

Mechanistic data showing a plausible immunomodulatory action in demyelinating disease
Preclinical studies in a relevant model of multiple sclerosis
Package insert warnings and contraindications from Health Canada
A risk-benefit comparison against approved disease-modifying therapies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.